NCT02369016
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02369016
Title Phase III Copanlisib in Rituximab-refractory iNHL
Acronym CHRONOS-2
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bayer
Indications
Therapies
Age Groups: adult
Covered Countries TUR | POL | ITA | GRC | BRA | BGR

Facility Status City State Zip Country Details
Jaú São Paulo 17210-120 Brazil Details
São Paulo São Paulo 08270-070 Brazil Details
São Paulo Brazil Details
Plovdiv 4000 Bulgaria Details
Athens 115 26 Greece Details
Bologna Emilia-Romagna 40138 Italy Details
Genoa Liguria 16132 Italy Details
Gdynia 81-519 Poland Details
Kazan' 420029 Russia Details
Kemerovo 650066 Russia Details
Moscow 123182 Russia Details
Omsk 644013 Russia Details
Penza 440071 Russia Details
Johannesburg Gauteng 2013 South Africa Details
Seoul Seoul Teugbyeolsi 03080 South Korea Details
Jeollabuk-do 561-712 South Korea Details
Jeollanam-do 58128 South Korea Details
Seoul 05505 South Korea Details
Seoul 3722 South Korea Details
Taipei 100 Taiwan Details
Istanbul 34093 Turkey (Türkiye) Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field